» Articles » PMID: 15477533

Clinical, Genetic, and Neuropathologic Characteristics of Posterior Cortical Atrophy

Overview
Journal Neurology
Specialty Neurology
Date 2004 Oct 13
PMID 15477533
Citations 259
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the clinical, genetic, and neuropathologic features of posterior cortical atrophy (PCA).

Design/methods: Using a broad definition of PCA as a syndrome with the insidious onset of visual dysfunction in the absence of primary ophthalmologic causes, the authors identified and then reviewed the presenting signs and symptoms, ApoE genotypes, tau haplotypes, and neuropathologic findings when available of PCA cases from two dementia research centers collected over the past 14 years.

Results: The authors identified 40 PCA cases. Their mean age at symptom onset was 60.5 +/- 8.9 years. There were twice as many women as men in the series. The principal types of visual impairment were simultanagnosia (82%) and visual field defect (47.5%). Acalculia, alexia, and anomia were also common. Insight was preserved in almost all (95%) early in the disorder. Neither apoE epsilon4 nor tau haplotype frequencies were different from typical Alzheimer disease (AD). Nine patients had died and underwent postmortem examination. Seven autopsied cases had AD pathology but when compared to typical AD, the neurofibrillary tangle (NFT) densities were significantly higher in Brodmann areas 17 and 18 (p < 0.05) and significantly lower in the hippocampus (p < 0.05). Two cases had corticobasal degeneration with maximal involvement of tau positive glial pathology in the posterior parietal lobe and Brodmann areas 17 and 18.

Conclusions: PCA is a distinctive dementia syndrome in which the most pronounced pathologic involvement is in the occipitoparietal regions independent of the specific underlying pathology. AD was the most common pathologic cause, but its regional distribution differed from typical AD.

Citing Articles

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Rabinovici G, Knopman D, Arbizu J, Benzinger T, Donohoe K, Hansson O Alzheimers Dement. 2025; 21(1):e14338.

PMID: 39776249 PMC: 11772739. DOI: 10.1002/alz.14338.


Effects of Route Complexity and Lighting on Route Following in Alzheimer's Disease and Posterior Cortical Atrophy.

Carton A, Frost C, Poole T, Yang B, McCarthy I, Suzuki T Brain Sci. 2025; 14(12.

PMID: 39766416 PMC: 11726922. DOI: 10.3390/brainsci14121217.


Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy.

Katsumi Y, Eckbo R, Chapleau M, Wong B, McGinnis S, Touroutoglou A Alzheimers Res Ther. 2024; 16(1):262.

PMID: 39696378 PMC: 11653806. DOI: 10.1186/s13195-024-01636-z.


Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy.

Katsumi Y, Eckbo R, Chapleau M, Wong B, McGinnis S, Touroutoglou A medRxiv. 2024; .

PMID: 39484250 PMC: 11527058. DOI: 10.1101/2024.10.15.24315270.


Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART.

Pelak V, Tang-Wai D, Boeve B, Bouwman F, Graff-Radford J, Rabinovici G Alzheimers Dement (Amst). 2024; 15(3):e12474.

PMID: 39329067 PMC: 11425198. DOI: 10.1002/dad2.12474.